Current Report Filing (8-k)
2020年4月18日 - 5:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April
13, 2020
Hepion Pharmaceuticals, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-36856
|
|
46-2783806
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
399 Thornall Street, First Floor
Edison, New Jersey
|
|
08837
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (732) 902-4000
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share
|
|
HEPA
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 1.01.
|
Entry into a Material Definitive Agreement
|
On April 13, 2020, Hepion Pharmaceuticals,
Inc. (the “Company”) was granted a loan (the “Loan”) from JPMorgan Chase Bank, N.A. in the aggregate amount
of $176,585, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which
was enacted March 27, 2020.
The Loan, which was in the form of a
Note dated April 13, 2020 issued by the Company, matures on April 13, 2022 and bears interest at a rate of 0.98% per annum,
payable monthly commencing on November 13, 2020. The Note may be prepaid by the Company at any time prior to maturity with no
prepayment penalties. Funds from the Loan may only be used for payroll costs, rent and utilities. The Company intends to use
the entire Loan amount for qualifying expenses. Under the terms of the PPP, certain amounts of the Loan may be forgiven if
they are used for qualifying expenses as described in the CARES Act.
Item 2.03.
|
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
|
Reference is made to the disclosure under
Item 1.01 above which is hereby incorporated in this Item 2.03 by reference.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 17, 2020
|
HEPION PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ Robert Foster
|
|
Name:
|
Robert Foster
|
|
Title:
|
Chief Executive Officer
|
Hepion Pharmaceuticals (PK) (USOTC:CTRVW)
過去 株価チャート
から 6 2024 まで 7 2024
Hepion Pharmaceuticals (PK) (USOTC:CTRVW)
過去 株価チャート
から 7 2023 まで 7 2024
Real-Time news about Hepion Pharmaceuticals Inc (PK) (その他OTC): 0 recent articles
その他のHepion Pharmaceuticals, Inc.ニュース記事